1.李金高, 陈晓钟, 林少俊,等. 鼻咽癌复发,转移诊断专家共识[J]. 中华放射肿瘤学杂志, 2018, 027(001):7-15.

2.Mai H Q, Chen Q Y, Chen D, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial[J]. Nature Medicine, 2021, 27(9): 1536-1543.

3.Thrift A P . Global burden and epidemiology of Barrett oesophagus and oesophageal cancer[J]. Nature Reviews Gastroenterology & Hepatology, 2021.

4.WHO. Age-standardized incidence, mortality rates (25-99 years) and 5-year net survival (15-99 years) in 2014, Oesophagus, both sexes. https://gco.iarc.fr/survival/survmark/visualizations/viz1/?groupby=%22country%22&period=%225%22&cancer_site=%22Oesophagus%22&country=%22Australia%22&year=%222014%22&gender=%22All%22&sorting=%220%22.

5.American Cancer Society. Survival Rates for Esophageal Cancer. https://www.cancer.org/cancer/esophagus-cancer/detection-diagnosis-staging/survival-rates.html.

6.Rui-Hua Xu，et al. JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021 ESMO 1373MO.

7.Sheng X, Yan X, Chi Z, et al. Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial[J]. Journal of Clinical Oncology, 2019, 37(32): 2987.

8.李思明,等. 特瑞普利单抗联合阿昔替尼治疗转移性黏膜黑色素瘤Ib期临床研究: 42个月随访结果及生物标志物分析.2021 CSCO.

9.Hu H, Kang L, Zhang J, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial[J]. The Lancet Gastroenterology & Hepatology, 2021.

10.Zhao Z R, Yang C P, Chen S, et al. Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer[J]. Oncoimmunology, 2021, 10(1): 1996000.

11.Luo M, Fu L. The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response[J]. Oncotarget, 2016, 7(20): 29794.

12.赵磊, 方芳, 陈琪. 免疫检查点抑制剂及联合放疗对肿瘤治疗的进展[J]. 现代免疫学, 2018, 38(2): 170-174.

13.钱磊, 冯继锋. 晚期非小细胞肺癌抗血管生成联合免疫治疗的理论基础及临床应用研究进展[J]. 山东医药, 2020, 60(15):4.

14.Fourcade J, Sun Z, Pagliano O, et al. CD8+ T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1[J]. Cancer research, 2012, 72(4): 887-896.

15.Chae Y K, Arya A, Iams W, et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)[J]. Journal for immunotherapy of cancer, 2018, 6(1): 1-27.

16.Rahimi Kalateh Shah Mohammad G, Ghahremanloo A, Soltani A, Fathi E, Hashemy SI. Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment. J Cell Physiol. 2020 Jul;235(7-8):5449-5460.